APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

9-valent Human Papillomavirus Vaccine

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global 9-valent Human Papillomavirus Vaccine Industry Growth and Trends Forecast to 2032

Report ID 173959240123 December 202592 pages

Choose your research edition.

Industry Research9-valent Human Papillomavirus Vaccine Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal 9-valent Human Papillomavirus Vaccine Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal 9-valent Human Papillomavirus Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal 9-valent Human Papillomavirus Vaccine Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal 9-valent Human Papillomavirus Vaccine Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global 9-valent Human Papillomavirus Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for 9-valent Human Papillomavirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for 9-valent Human Papillomavirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for 9-valent Human Papillomavirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of 9-valent Human Papillomavirus Vaccine include Zhifei Biological Products, Walvax Biotechnology, Wantai Biological Pharmacy, GSK, Beijing Health Guard Biotechnology and Merck Group, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global 9-valent Human Papillomavirus Vaccine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The 9-valent Human Papillomavirus Vaccine market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global 9-valent Human Papillomavirus Vaccine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to 9-valent Human Papillomavirus Vaccine.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global 9-valent Human Papillomavirus Vaccine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

9-valent Human Papillomavirus Vaccine Market by Company

Zhifei Biological Products

Walvax Biotechnology

Wantai Biological Pharmacy

GSK

Beijing Health Guard Biotechnology

Merck Group

9-valent Human Papillomavirus Vaccine Segment by Type

HPV11

HPV16

HPV18

HPV6

Others

9-valent Human Papillomavirus Vaccine Segment by Application

Health Center

Epidemic Prevention Station

Hospital

Others

9-valent Human Papillomavirus Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global 9-valent Human Papillomavirus Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of 9-valent Human Papillomavirus Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of 9-valent Human Papillomavirus Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of 9-valent Human Papillomavirus Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of 9-valent Human Papillomavirus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of HPV11 Table 2. Major Company of HPV16 Table 3. Major Company of HPV18 Table 4. Major Company of HPV6 Table 5. Major Company of Others Table 6. Global 9-valent Human Papillomavirus Vaccine Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global 9-valent Human Papillomavirus Vaccine Sales by Type (2021-2026) & (k units) Table 8. Global 9-valent Human Papillomavirus Vaccine Sales Market Share in Volume by Type (2021-2026) Table 9. Global 9-valent Human Papillomavirus Vaccine Sales by Type (2021-2026) & (US$ Million) Table 10. Global 9-valent Human Papillomavirus Vaccine Sales Market Share in Value by Type (2021-2026) Table 11. Global 9-valent Human Papillomavirus Vaccine Price by Type (2021-2026) & (USD/unit) Table 12. Global 9-valent Human Papillomavirus Vaccine Sales by Type (2027-2032) & (k units) Table 13. Global 9-valent Human Papillomavirus Vaccine Sales Market Share in Volume by Type (2027-2032) Table 14. Global 9-valent Human Papillomavirus Vaccine Sales by Type (2027-2032) & (US$ Million) Table 15. Global 9-valent Human Papillomavirus Vaccine Sales Market Share in Value by Type (2027-2032) Table 16. Global 9-valent Human Papillomavirus Vaccine Price by Type (2027-2032) & (USD/unit) Table 17. North America 9-valent Human Papillomavirus Vaccine Sales by Type (2021-2026) & (k units) Table 18. North America 9-valent Human Papillomavirus Vaccine Sales by Type (2021-2026) & (US$ Million) Table 19. Europe 9-valent Human Papillomavirus Vaccine Sales by Type (2021-2026) & (k units) Table 20. Europe 9-valent Human Papillomavirus Vaccine Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific 9-valent Human Papillomavirus Vaccine Sales by Type (2021-2026) & (k units) Table 22. Asia-Pacific 9-valent Human Papillomavirus Vaccine Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America 9-valent Human Papillomavirus Vaccine Sales by Type (2021-2026) & (k units) Table 24. Latin America 9-valent Human Papillomavirus Vaccine Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales by Type (2021-2026) & (k units) Table 26. Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales by Type (2021-2026) & (US$ Million) Table 27. 9-valent Human Papillomavirus Vaccine Industry Trends Table 28. 9-valent Human Papillomavirus Vaccine Industry Drivers Table 29. 9-valent Human Papillomavirus Vaccine Industry Opportunities and Challenges Table 30. 9-valent Human Papillomavirus Vaccine Industry Restraints Table 31. Global 9-valent Human Papillomavirus Vaccine Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Company (2021-2026) Table 33. Global 9-valent Human Papillomavirus Vaccine Sales by Company (2021-2026) & (k units) Table 34. Global 9-valent Human Papillomavirus Vaccine Sales Share by Company (2021-2026) Table 35. Global 9-valent Human Papillomavirus Vaccine Market Price by Company (2021-2026) & (USD/unit) Table 36. Global 9-valent Human Papillomavirus Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global 9-valent Human Papillomavirus Vaccine Major Company Production Sites and Headquarters Table 38. Global 9-valent Human Papillomavirus Vaccine Company, Product Type & Application Table 39. Global 9-valent Human Papillomavirus Vaccine Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global 9-valent Human Papillomavirus Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global 9-valent Human Papillomavirus Vaccine Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global 9-valent Human Papillomavirus Vaccine Sales by Region (2021-2026) & (k units) Table 44. Global 9-valent Human Papillomavirus Vaccine Sales Market Share in Volume by Region (2021-2026) Table 45. Global 9-valent Human Papillomavirus Vaccine Sales by Region (2021-2026) & (US$ Million) Table 46. Global 9-valent Human Papillomavirus Vaccine Sales Market Share in Value by Region (2021-2026) Table 47. Global 9-valent Human Papillomavirus Vaccine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 48. Global 9-valent Human Papillomavirus Vaccine Sales by Region (2027-2032) & (k units) Table 49. Global 9-valent Human Papillomavirus Vaccine Sales Market Share in Volume by Region (2027-2032) Table 50. Global 9-valent Human Papillomavirus Vaccine Sales by Region (2027-2032) & (US$ Million) Table 51. Global 9-valent Human Papillomavirus Vaccine Sales Market Share in Value by Region (2027-2032) Table 52. Global 9-valent Human Papillomavirus Vaccine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2027-2032) Table 53. Global 9-valent Human Papillomavirus Vaccine Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global 9-valent Human Papillomavirus Vaccine Sales by Application (2021-2026) & (k units) Table 55. Global 9-valent Human Papillomavirus Vaccine Sales Market Share in Volume by Application (2021-2026) Table 56. Global 9-valent Human Papillomavirus Vaccine Sales by Application (2021-2026) & (US$ Million) Table 57. Global 9-valent Human Papillomavirus Vaccine Sales Market Share in Value by Application (2021-2026) Table 58. Global 9-valent Human Papillomavirus Vaccine Price by Application (2021-2026) & (USD/unit) Table 59. Global 9-valent Human Papillomavirus Vaccine Sales by Application (2027-2032) & (k units) Table 60. Global 9-valent Human Papillomavirus Vaccine Sales Market Share in Volume by Application (2027-2032) Table 61. Global 9-valent Human Papillomavirus Vaccine Sales by Application (2027-2032) & (US$ Million) Table 62. Global 9-valent Human Papillomavirus Vaccine Sales Market Share in Value by Application (2027-2032) Table 63. Global 9-valent Human Papillomavirus Vaccine Price by Application (2027-2032) & (USD/unit) Table 64. North America 9-valent Human Papillomavirus Vaccine Sales by Application (2021-2026) & (k units) Table 65. North America 9-valent Human Papillomavirus Vaccine Sales by Application (2021-2026) & (US$ Million) Table 66. Europe 9-valent Human Papillomavirus Vaccine Sales by Application (2021-2026) & (k units) Table 67. Europe 9-valent Human Papillomavirus Vaccine Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific 9-valent Human Papillomavirus Vaccine Sales by Application (2021-2026) & (k units) Table 69. Asia-Pacific 9-valent Human Papillomavirus Vaccine Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America 9-valent Human Papillomavirus Vaccine Sales by Application (2021-2026) & (k units) Table 71. Latin America 9-valent Human Papillomavirus Vaccine Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales by Application (2021-2026) & (k units) Table 73. Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales by Application (2021-2026) & (US$ Million) Table 74. Zhifei Biological Products Company Information Table 75. Zhifei Biological Products Business Overview Table 76. Zhifei Biological Products 9-valent Human Papillomavirus Vaccine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 77. Zhifei Biological Products 9-valent Human Papillomavirus Vaccine Product Portfolio Table 78. Zhifei Biological Products Recent Development Table 79. Walvax Biotechnology Company Information Table 80. Walvax Biotechnology Business Overview Table 81. Walvax Biotechnology 9-valent Human Papillomavirus Vaccine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 82. Walvax Biotechnology 9-valent Human Papillomavirus Vaccine Product Portfolio Table 83. Walvax Biotechnology Recent Development Table 84. Wantai Biological Pharmacy Company Information Table 85. Wantai Biological Pharmacy Business Overview Table 86. Wantai Biological Pharmacy 9-valent Human Papillomavirus Vaccine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 87. Wantai Biological Pharmacy 9-valent Human Papillomavirus Vaccine Product Portfolio Table 88. Wantai Biological Pharmacy Recent Development Table 89. GSK Company Information Table 90. GSK Business Overview Table 91. GSK 9-valent Human Papillomavirus Vaccine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. GSK 9-valent Human Papillomavirus Vaccine Product Portfolio Table 93. GSK Recent Development Table 94. Beijing Health Guard Biotechnology Company Information Table 95. Beijing Health Guard Biotechnology Business Overview Table 96. Beijing Health Guard Biotechnology 9-valent Human Papillomavirus Vaccine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Beijing Health Guard Biotechnology 9-valent Human Papillomavirus Vaccine Product Portfolio Table 98. Beijing Health Guard Biotechnology Recent Development Table 99. Merck Group Company Information Table 100. Merck Group Business Overview Table 101. Merck Group 9-valent Human Papillomavirus Vaccine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. Merck Group 9-valent Human Papillomavirus Vaccine Product Portfolio Table 103. Merck Group Recent Development Table 104. North America 9-valent Human Papillomavirus Vaccine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 105. North America 9-valent Human Papillomavirus Vaccine Sales by Country (2021-2026) & (k units) Table 106. North America 9-valent Human Papillomavirus Vaccine Sales Market Share by Country (2021-2026) Table 107. North America 9-valent Human Papillomavirus Vaccine Sales Forecast by Country (2027-2032) & (k units) Table 108. North America 9-valent Human Papillomavirus Vaccine Sales Market Share Forecast by Country (2027-2032) Table 109. North America 9-valent Human Papillomavirus Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 110. North America 9-valent Human Papillomavirus Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 111. North America 9-valent Human Papillomavirus Vaccine Market Share by Country (2021-2026) Table 112. North America 9-valent Human Papillomavirus Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 113. North America 9-valent Human Papillomavirus Vaccine Market Share Forecast by Country (2027-2032) Table 114. Europe 9-valent Human Papillomavirus Vaccine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 115. Europe 9-valent Human Papillomavirus Vaccine Sales by Country (2021-2026) & (k units) Table 116. Europe 9-valent Human Papillomavirus Vaccine Sales Market Share by Country (2021-2026) Table 117. Europe 9-valent Human Papillomavirus Vaccine Sales Forecast by Country (2027-2032) & (k units) Table 118. Europe 9-valent Human Papillomavirus Vaccine Sales Market Share Forecast by Country (2027-2032) Table 119. Europe 9-valent Human Papillomavirus Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 120. Europe 9-valent Human Papillomavirus Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 121. Europe 9-valent Human Papillomavirus Vaccine Market Share by Country (2021-2026) Table 122. Europe 9-valent Human Papillomavirus Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 123. Europe 9-valent Human Papillomavirus Vaccine Market Share Forecast by Country (2027-2032) Table 124. Asia-Pacific 9-valent Human Papillomavirus Vaccine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 125. Asia-Pacific 9-valent Human Papillomavirus Vaccine Sales by Country (2021-2026) & (k units) Table 126. Asia-Pacific 9-valent Human Papillomavirus Vaccine Sales Market Share by Country (2021-2026) Table 127. Asia-Pacific 9-valent Human Papillomavirus Vaccine Sales Forecast by Country (2027-2032) & (k units) Table 128. Asia-Pacific 9-valent Human Papillomavirus Vaccine Sales Market Share Forecast by Country (2027-2032) Table 129. Asia-Pacific 9-valent Human Papillomavirus Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 130. Asia-Pacific 9-valent Human Papillomavirus Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 131. Asia-Pacific 9-valent Human Papillomavirus Vaccine Market Share by Country (2021-2026) Table 132. Asia-Pacific 9-valent Human Papillomavirus Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 133. Asia-Pacific 9-valent Human Papillomavirus Vaccine Market Share Forecast by Country (2027-2032) Table 134. Latin America 9-valent Human Papillomavirus Vaccine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 135. Latin America 9-valent Human Papillomavirus Vaccine Sales by Country (2021-2026) & (k units) Table 136. Latin America 9-valent Human Papillomavirus Vaccine Sales Market Share by Country (2021-2026) Table 137. Latin America 9-valent Human Papillomavirus Vaccine Sales Forecast by Country (2027-2032) & (k units) Table 138. Latin America 9-valent Human Papillomavirus Vaccine Sales Market Share Forecast by Country (2027-2032) Table 139. Latin America 9-valent Human Papillomavirus Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 140. Latin America 9-valent Human Papillomavirus Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 141. Latin America 9-valent Human Papillomavirus Vaccine Market Share by Country (2021-2026) Table 142. Latin America 9-valent Human Papillomavirus Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 143. Latin America 9-valent Human Papillomavirus Vaccine Market Share Forecast by Country (2027-2032) Table 144. Middle East and Africa 9-valent Human Papillomavirus Vaccine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 145. Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales by Country (2021-2026) & (k units) Table 146. Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales Market Share by Country (2021-2026) Table 147. Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales Forecast by Country (2027-2032) & (k units) Table 148. Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales Market Share Forecast by Country (2027-2032) Table 149. Middle East and Africa 9-valent Human Papillomavirus Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 150. Middle East and Africa 9-valent Human Papillomavirus Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 151. Middle East and Africa 9-valent Human Papillomavirus Vaccine Market Share by Country (2021-2026) Table 152. Middle East and Africa 9-valent Human Papillomavirus Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 153. Middle East and Africa 9-valent Human Papillomavirus Vaccine Market Share Forecast by Country (2027-2032) Table 154. Key Raw Materials Table 155. Raw Materials Key Suppliers Table 156. 9-valent Human Papillomavirus Vaccine Distributors List Table 157. 9-valent Human Papillomavirus Vaccine Customers List Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources Table 161. Primary Sources List of Figures Figure 1. 9-valent Human Papillomavirus Vaccine Image Figure 2. Global 9-valent Human Papillomavirus Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global 9-valent Human Papillomavirus Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global 9-valent Human Papillomavirus Vaccine Sales (2021-2032) & (k units) Figure 5. HPV11 Image Figure 6. Global HPV11 Sales YoY Growth (2021-2032) & (k units) Figure 7. HPV16 Image Figure 8. Global HPV16 Sales YoY Growth (2021-2032) & (k units) Figure 9. HPV18 Image Figure 10. Global HPV18 Sales YoY Growth (2021-2032) & (k units) Figure 11. HPV6 Image Figure 12. Global HPV6 Sales YoY Growth (2021-2032) & (k units) Figure 13. Others Image Figure 14. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 15. Global 9-valent Human Papillomavirus Vaccine Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global 9-valent Human Papillomavirus Vaccine Market Share by Type 2025 VS 2032 Figure 17. North America 9-valent Human Papillomavirus Vaccine Sales Market Share in Volume by Type in 2025 Figure 18. North America 9-valent Human Papillomavirus Vaccine Sales Market Share in Value by Type in 2025 Figure 19. Europe 9-valent Human Papillomavirus Vaccine Sales Market Share in Volume by Type in 2025 Figure 20. Europe 9-valent Human Papillomavirus Vaccine Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific 9-valent Human Papillomavirus Vaccine Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific 9-valent Human Papillomavirus Vaccine Sales Market Share in Value by Type in 2025 Figure 23. Latin America 9-valent Human Papillomavirus Vaccine Sales Market Share in Volume by Type in 2025 Figure 24. Latin America 9-valent Human Papillomavirus Vaccine Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 9-valent Human Papillomavirus Vaccine Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Health Center Image Figure 30. Global Health Center Sales YoY Growth (2021-2032) & (k units) Figure 31. Epidemic Prevention Station Image Figure 32. Global Epidemic Prevention Station Sales YoY Growth (2021-2032) & (k units) Figure 33. Hospital Image Figure 34. Global Hospital Sales YoY Growth (2021-2032) & (k units) Figure 35. Others Image Figure 36. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 37. Global 9-valent Human Papillomavirus Vaccine Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global 9-valent Human Papillomavirus Vaccine Market Share by Application 2025 VS 2032 Figure 39. North America 9-valent Human Papillomavirus Vaccine Sales Market Share in Volume by Application in 2025 Figure 40. North America 9-valent Human Papillomavirus Vaccine Sales Market Share in Value by Application in 2025 Figure 41. Europe 9-valent Human Papillomavirus Vaccine Sales Market Share in Volume by Application in 2025 Figure 42. Europe 9-valent Human Papillomavirus Vaccine Sales Market Share in Value by Application in 2025 Figure 43. Asia-Pacific 9-valent Human Papillomavirus Vaccine Sales Market Share in Volume by Application in 2025 Figure 44. Asia-Pacific 9-valent Human Papillomavirus Vaccine Sales Market Share in Value by Application in 2025 Figure 45. Latin America 9-valent Human Papillomavirus Vaccine Sales Market Share in Volume by Application in 2025 Figure 46. Latin America 9-valent Human Papillomavirus Vaccine Sales Market Share in Value by Application in 2025 Figure 47. Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales Market Share in Volume by Application in 2025 Figure 48. Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales Market Share in Value by Application in 2025 Figure 49. North America 9-valent Human Papillomavirus Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. North America 9-valent Human Papillomavirus Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. North America 9-valent Human Papillomavirus Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. North America 9-valent Human Papillomavirus Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe 9-valent Human Papillomavirus Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Europe 9-valent Human Papillomavirus Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe 9-valent Human Papillomavirus Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Europe 9-valent Human Papillomavirus Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific 9-valent Human Papillomavirus Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Asia-Pacific 9-valent Human Papillomavirus Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific 9-valent Human Papillomavirus Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Asia-Pacific 9-valent Human Papillomavirus Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America 9-valent Human Papillomavirus Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 62. Latin America 9-valent Human Papillomavirus Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America 9-valent Human Papillomavirus Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America 9-valent Human Papillomavirus Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 66. Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa 9-valent Human Papillomavirus Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Middle East and Africa 9-valent Human Papillomavirus Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. 9-valent Human Papillomavirus Vaccine Value Chain Figure 70. Key Raw Materials Price Figure 71. Manufacturing Cost Structure Figure 72. 9-valent Human Papillomavirus Vaccine Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • HPV11
  • HPV16
  • HPV18
  • HPV6
  • Others
Applications
  • Health Center
  • Epidemic Prevention Station
  • Hospital
  • Others
Companies covered
  • Zhifei Biological Products
  • Walvax Biotechnology
  • Wantai Biological Pharmacy
  • GSK
  • Beijing Health Guard Biotechnology
  • Merck Group

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global 9-valent Human Papillomavirus Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global 9-valent Human Papillomavirus Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.3 9-valent Human Papillomavirus Vaccine Market by Type
  6. 1.3.1 HPV11
  7. 1.3.2 HPV16
  8. 1.3.3 HPV18
  9. 1.3.4 HPV6
  10. 1.3.5 Others
  11. 1.4 Global 9-valent Human Papillomavirus Vaccine Market Size by Type
  12. 1.4.1 Global 9-valent Human Papillomavirus Vaccine Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global 9-valent Human Papillomavirus Vaccine Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global 9-valent Human Papillomavirus Vaccine Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America 9-valent Human Papillomavirus Vaccine Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe 9-valent Human Papillomavirus Vaccine Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific 9-valent Human Papillomavirus Vaccine Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America 9-valent Human Papillomavirus Vaccine Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 9-valent Human Papillomavirus Vaccine Industry Trends
  2. 2.2 9-valent Human Papillomavirus Vaccine Industry Drivers
  3. 2.3 9-valent Human Papillomavirus Vaccine Industry Opportunities and Challenges
  4. 2.4 9-valent Human Papillomavirus Vaccine Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by 9-valent Human Papillomavirus Vaccine Revenue (2021-2026)
  2. 3.2 Global Top Players by 9-valent Human Papillomavirus Vaccine Sales (2021-2026)
  3. 3.3 Global Top Players by 9-valent Human Papillomavirus Vaccine Price (2021-2026)
  4. 3.4 Global 9-valent Human Papillomavirus Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global 9-valent Human Papillomavirus Vaccine Major Company Production Sites & Headquarters
  6. 3.6 Global 9-valent Human Papillomavirus Vaccine Company, Product Type & Application
  7. 3.7 Global 9-valent Human Papillomavirus Vaccine Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global 9-valent Human Papillomavirus Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 9-valent Human Papillomavirus Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 9-valent Human Papillomavirus Vaccine Tier 1, Tier 2, and Tier 3
4 9-valent Human Papillomavirus Vaccine Regional Status and Outlook
  1. 4.1 Global 9-valent Human Papillomavirus Vaccine Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global 9-valent Human Papillomavirus Vaccine Historic Market Size by Region
  3. 4.2.1 Global 9-valent Human Papillomavirus Vaccine Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global 9-valent Human Papillomavirus Vaccine Sales in Value by Region (2021-2026)
  5. 4.2.3 Global 9-valent Human Papillomavirus Vaccine Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global 9-valent Human Papillomavirus Vaccine Forecasted Market Size by Region
  7. 4.3.1 Global 9-valent Human Papillomavirus Vaccine Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global 9-valent Human Papillomavirus Vaccine Sales in Value by Region (2027-2032)
  9. 4.3.3 Global 9-valent Human Papillomavirus Vaccine Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 9-valent Human Papillomavirus Vaccine by Application
  1. 5.1 9-valent Human Papillomavirus Vaccine Market by Application
  2. 5.1.1 Health Center
  3. 5.1.2 Epidemic Prevention Station
  4. 5.1.3 Hospital
  5. 5.1.4 Others
  6. 5.2 Global 9-valent Human Papillomavirus Vaccine Market Size by Application
  7. 5.2.1 Global 9-valent Human Papillomavirus Vaccine Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global 9-valent Human Papillomavirus Vaccine Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global 9-valent Human Papillomavirus Vaccine Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America 9-valent Human Papillomavirus Vaccine Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe 9-valent Human Papillomavirus Vaccine Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific 9-valent Human Papillomavirus Vaccine Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America 9-valent Human Papillomavirus Vaccine Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Zhifei Biological Products
  2. 6.1.1 Zhifei Biological Products Company Information
  3. 6.1.2 Zhifei Biological Products Business Overview
  4. 6.1.3 Zhifei Biological Products 9-valent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Zhifei Biological Products 9-valent Human Papillomavirus Vaccine Product Portfolio
  6. 6.1.5 Zhifei Biological Products Recent Developments
  7. 6.2 Walvax Biotechnology
  8. 6.2.1 Walvax Biotechnology Company Information
  9. 6.2.2 Walvax Biotechnology Business Overview
  10. 6.2.3 Walvax Biotechnology 9-valent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Walvax Biotechnology 9-valent Human Papillomavirus Vaccine Product Portfolio
  12. 6.2.5 Walvax Biotechnology Recent Developments
  13. 6.3 Wantai Biological Pharmacy
  14. 6.3.1 Wantai Biological Pharmacy Company Information
  15. 6.3.2 Wantai Biological Pharmacy Business Overview
  16. 6.3.3 Wantai Biological Pharmacy 9-valent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Wantai Biological Pharmacy 9-valent Human Papillomavirus Vaccine Product Portfolio
  18. 6.3.5 Wantai Biological Pharmacy Recent Developments
  19. 6.4 GSK
  20. 6.4.1 GSK Company Information
  21. 6.4.2 GSK Business Overview
  22. 6.4.3 GSK 9-valent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 GSK 9-valent Human Papillomavirus Vaccine Product Portfolio
  24. 6.4.5 GSK Recent Developments
  25. 6.5 Beijing Health Guard Biotechnology
  26. 6.5.1 Beijing Health Guard Biotechnology Company Information
  27. 6.5.2 Beijing Health Guard Biotechnology Business Overview
  28. 6.5.3 Beijing Health Guard Biotechnology 9-valent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Beijing Health Guard Biotechnology 9-valent Human Papillomavirus Vaccine Product Portfolio
  30. 6.5.5 Beijing Health Guard Biotechnology Recent Developments
  31. 6.6 Merck Group
  32. 6.6.1 Merck Group Company Information
  33. 6.6.2 Merck Group Business Overview
  34. 6.6.3 Merck Group 9-valent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Merck Group 9-valent Human Papillomavirus Vaccine Product Portfolio
  36. 6.6.5 Merck Group Recent Developments
7 North America by Country
  1. 7.1 North America 9-valent Human Papillomavirus Vaccine Sales by Country
  2. 7.1.1 North America 9-valent Human Papillomavirus Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America 9-valent Human Papillomavirus Vaccine Sales by Country (2021-2026)
  4. 7.1.3 North America 9-valent Human Papillomavirus Vaccine Sales Forecast by Country (2027-2032)
  5. 7.2 North America 9-valent Human Papillomavirus Vaccine Market Size by Country
  6. 7.2.1 North America 9-valent Human Papillomavirus Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America 9-valent Human Papillomavirus Vaccine Market Size by Country (2021-2026)
  8. 7.2.3 North America 9-valent Human Papillomavirus Vaccine Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe 9-valent Human Papillomavirus Vaccine Sales by Country
  2. 8.1.1 Europe 9-valent Human Papillomavirus Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe 9-valent Human Papillomavirus Vaccine Sales by Country (2021-2026)
  4. 8.1.3 Europe 9-valent Human Papillomavirus Vaccine Sales Forecast by Country (2027-2032)
  5. 8.2 Europe 9-valent Human Papillomavirus Vaccine Market Size by Country
  6. 8.2.1 Europe 9-valent Human Papillomavirus Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe 9-valent Human Papillomavirus Vaccine Market Size by Country (2021-2026)
  8. 8.2.3 Europe 9-valent Human Papillomavirus Vaccine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific 9-valent Human Papillomavirus Vaccine Sales by Country
  2. 9.1.1 Asia-Pacific 9-valent Human Papillomavirus Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific 9-valent Human Papillomavirus Vaccine Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific 9-valent Human Papillomavirus Vaccine Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific 9-valent Human Papillomavirus Vaccine Market Size by Country
  6. 9.2.1 Asia-Pacific 9-valent Human Papillomavirus Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific 9-valent Human Papillomavirus Vaccine Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific 9-valent Human Papillomavirus Vaccine Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America 9-valent Human Papillomavirus Vaccine Sales by Country
  2. 10.1.1 South America 9-valent Human Papillomavirus Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America 9-valent Human Papillomavirus Vaccine Sales by Country (2021-2026)
  4. 10.1.3 South America 9-valent Human Papillomavirus Vaccine Sales Forecast by Country (2027-2032)
  5. 10.2 South America 9-valent Human Papillomavirus Vaccine Market Size by Country
  6. 10.2.1 South America 9-valent Human Papillomavirus Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America 9-valent Human Papillomavirus Vaccine Market Size by Country (2021-2026)
  8. 10.2.3 South America 9-valent Human Papillomavirus Vaccine Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales by Country
  2. 11.1.1 Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa 9-valent Human Papillomavirus Vaccine Market Size by Country
  6. 11.2.1 Middle East and Africa 9-valent Human Papillomavirus Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa 9-valent Human Papillomavirus Vaccine Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa 9-valent Human Papillomavirus Vaccine Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 9-valent Human Papillomavirus Vaccine Value Chain Analysis
  2. 12.1.1 9-valent Human Papillomavirus Vaccine Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 9-valent Human Papillomavirus Vaccine Production Mode & Process
  7. 12.2 9-valent Human Papillomavirus Vaccine Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 9-valent Human Papillomavirus Vaccine Distributors
  10. 12.2.3 9-valent Human Papillomavirus Vaccine Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst